0001181431-14-024372.txt : 20140625 0001181431-14-024372.hdr.sgml : 20140625 20140618160233 ACCESSION NUMBER: 0001181431-14-024372 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140616 FILED AS OF DATE: 20140618 DATE AS OF CHANGE: 20140618 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ROUTE 141 & HENRY CLAY ROAD STREET 2: BUILDING E336 CITY: WILMINGTON STATE: DE ZIP: 19880 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: ROUTE 141 & HENRY CLAY ROAD STREET 2: BUILDING E336 CITY: WILMINGTON STATE: DE ZIP: 19880 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Levy Richard S CENTRAL INDEX KEY: 0001454983 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 14928147 MAIL ADDRESS: STREET 1: EXPERIMENTAL STATION STREET 2: ROUTE 141 AND HENRY CLAY RD CITY: WILMINGTON STATE: DE ZIP: 19880 4 1 rrd411871.xml X0306 4 2014-06-16 0 0000879169 INCYTE CORP INCY 0001454983 Levy Richard S EXPERIMENTAL STATION ROUTE 141 AND HENRY CLAY RD WILMINGTON DE 19880 0 1 0 0 EVP, Chief Drug Dev&Medical Of Common Stock 2014-06-16 4 M 0 8000 14.72 A 12301 D Common Stock 2014-06-16 4 S 0 8000 53.88 D 4301 D Non-Qualified Stock Option (right to buy) 14.72 2014-06-16 4 M 0 8000 0 D 2018-01-24 Common Stock 8000 76317 D Beginning January 25, 2011, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Represents weighted average sale price. Actual sales prices ranged from $53.44 - $54.32. Reporting person undertakes to provide upon request by Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares. /s/ Eric Siegel, Attorney In Fact 2014-06-18